Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
S&P Global
SPGI
|
+$677M |
| 2 |
AGN
Allergan plc
AGN
|
+$437M |
| 3 |
Qualcomm
QCOM
|
+$387M |
| 4 |
lululemon athletica
LULU
|
+$366M |
| 5 |
NVIDIA
NVDA
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Under Armour
UAA
|
+$1.03B |
| 2 |
Abbott
ABT
|
+$767M |
| 3 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$627M |
| 4 |
Meta Platforms (Facebook)
META
|
+$520M |
| 5 |
Nike
NKE
|
+$454M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 19.09% |
| 2 | Healthcare | 16.64% |
| 3 | Technology | 14.97% |
| 4 | Communication Services | 12.63% |
| 5 | Financials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
501
DELISTED
Chimerix, Inc.
CMRX
| $5.04M | 0.01% |
1,282,604
-1,466
| -0.1% | -$7.24K |
|
502
ExxonMobil
XOM
$615B
| $4.77M | 0.01% |
50,925
-1,117
| -2% | -$98.8K |
|
|
LNKD
503
DELISTED
LinkedIn Corporation
LNKD
| $4.65M | 0.01% |
24,592
-291,788
| -92% | -$40.4M |
|
|
ENBL
504
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
| $4.54M | 0.01% |
+335,976
| New | +$4.17M |
|
|
TRVN
505
DELISTED
Trevena, Inc.
TRVN
| $4.45M | ﹤0.01% |
1,130
-2
| -0.2% | -$9.39K |
|
506
Editas Medicine
EDIT
$442M
| $4.13M | ﹤0.01% |
170,940
| – | – |
|
|
LJPC
507
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $4.04M | ﹤0.01% |
252,437
+3,863
| +2% | +$69.3K |
|
|
VWR
508
DELISTED
VWR Corporation
VWR
| $3.97M | ﹤0.01% |
+137,373
| New | +$3.85M |
|
|
GBT
509
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.94M | ﹤0.01% |
237,172
-145
| -0.1% | -$2.92K |
|
510
BioCryst Pharmaceuticals
BCRX
$2.34B
| $3.85M | ﹤0.01% |
1,356,302
-1,302
| -0.1% | -$4.04K |
|
511
Plains GP Holdings
PAGP
$5.13B
| $3.56M | ﹤0.01% |
128,032
+5,668
| +5% | +$146K |
|
512
Johnson & Johnson
JNJ
$600B
| $3.49M | ﹤0.01% |
28,805
-678
| -2% | -$77K |
|
513
Gartner
IT
$9.46B
| $3.41M | ﹤0.01% |
34,999
| – | – |
|
514
Intel
INTC
$492B
| $3.4M | ﹤0.01% |
103,706
+328
| +0.3% | +$10.3K |
|
515
Liberty Latin America Class C
LILAK
$1.47B
| $3.38M | ﹤0.01% |
+121,468
| New | +$4.03M |
|
516
Coca-Cola
KO
$352B
| $3.36M | ﹤0.01% |
74,151
-973,246
| -93% | -$44M |
|
517
Evercore
EVR
$12.9B
| $3.35M | ﹤0.01% |
+75,852
| New | +$3.78M |
|
518
Baxter International
BAX
$11.5B
| $3.33M | ﹤0.01% |
+73,747
| New | +$3.23M |
|
|
ADAP
519
DELISTED
Adaptimmune Therapeutics
ADAP
| $3.28M | ﹤0.01% |
402,609
-358
| -0.1% | -$3.37K |
|
520
Berkshire Hathaway Class B
BRK.B
$1.06T
| $3.26M | ﹤0.01% |
22,505
-309
| -1% | -$44.2K |
|
521
Elevance Health
ELV
$83.2B
| $3.17M | ﹤0.01% |
24,115
+517
| +2% | +$70.7K |
|
522
PTC Therapeutics
PTCT
$6.48B
| $3.13M | ﹤0.01% |
446,000
+179,720
| +67% | +$1.32M |
|
|
TCP
523
DELISTED
TC Pipelines LP
TCP
| $3.08M | ﹤0.01% |
+53,831
| New | +$2.92M |
|
524
Waste Management
WM
$96B
| $3.04M | ﹤0.01% |
+45,890
| New | +$2.77M |
|
|
BNY
525
Bank of New York Mellon
BNY
$108B
| $2.98M | ﹤0.01% |
76,624
-8,446
| -10% | -$336K |
|
Similar funds
Jennison Associates's Q2 2016 Portfolio in Review
As of Q2 2016, Jennison Associates held 691 positions worth $91.1B, down 4.3% from $95.3B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Jennison Associates withdrew a net $4.67B in Q2 2016, closing 61 positions and reducing 333 holdings. Its most notable exit was MCGRAW-HILL FINANCIAL INC COM, an estimated $627M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Jennison Associates opened a new position in S&P Global worth $677M.
- Jennison Associates's largest Q2 2016 buy was S&P Global: 6,307,763 shares worth $677M.
- Jennison Associates added most to Allergan plc in Q2 2016, an estimated $437M increase.
- Jennison Associates's biggest Q2 2016 reduction was Under Armour, cutting an estimated $1.03B.
- Jennison Associates fully exited MCGRAW-HILL FINANCIAL INC COM in Q2 2016, selling an estimated $627M.
- Jennison Associates's ten largest holdings make up 23% of its $91.1B portfolio in Q2 2016.
- Jennison Associates opened 83 new positions and closed 61 in Q2 2016.
- Jennison Associates's portfolio value fell 4.3% quarter-over-quarter to $91.1B.
Based on Jennison Associates's 13F filing for Q2 2016, filed 3 Aug 2016.